Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
Date: May 6, 2019
Issue #:
1571Summary:
The FDA has approved siponimod (Mayzent–
Novartis), a sphingosine 1-phosphate (S1P) receptor
modulator, for oral treatment of adults with relapsing
forms of multiple sclerosis (MS), including clinically
isolated syndrome (initial neurological episode),
relapsing-remitting disease, and active secondary
progressive MS (SPMS). Siponimod i s the second
S1P receptor modulator to be approved in the US;
fingolimod(Gilenya), which is approved for oral
treatment of relapsing forms of MS in patients≥10
years old, was the first. The purine antimetabolite
cladribine(Mavenclad) was also recently approved
for oral treatment of relapsing forms of MS and will be
reviewed in a future issue.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Cladribine dimethyl fumarate Fingolimod Gilenya Glatect Glatiramer acetate Glatopa interferod beta Lemtrada Mavenclad Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Plegridy sipo Source Type: research
More News: Avonex | Brain | Copaxone | Drugs & Pharmacology | Gilenya | Multiple Sclerosis | Neurology | Rebif | Tysabri